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Effect of Cinnamomum Verum Extract on the Amyloid Forma-
tion of Hen Egg-white Lysozyme and Study of its Possible Role in 
Alzheimer’s Disease
Introduction: Diagnosing and treating diseases associated with amyloid fibers remain a great 
challenge despite of intensive research carried out. One important approach in the development 
of therapeutics is the use of herbal extracts which are rich in aromatic small molecules. 
Cinnamomum verum extract (CE) contains proanthocyanidin and cinnamaldehyde, which have 
been suggested to be capable of directly inhibiting amyloid fibril formation in vitro. This study 
is aimed at characterizing the inhibitory activity of CE against the fibrillation of hen egg white 
lysozyme (HEWL).
Methods: Acidic pH and high temperatures were used to drive the protein towards amyloid 
formation. Lysozyme was dissolved at 2 mg/mL in 50mM glycine buffer (pH 2.5), and then 
incubated at 57 °C for the specified durations while stirred gently by Teflon magnetic bars. 
Various techniques including thioflavin T, fluorescence, Congo red absorbance assay and AFM 
micrography were used to characterize the HEWL fibrillation processes.
Results: In the absence of CE typical amyloid fibrils (like amyloids formed in Alzheimer disease) 
became evident after 48 h of incubation. Upon incubation with various extract concentrations in 
the range of 0.1-1 mg/ml, formation of fibrillar assemblies were significantly inhibited (P<0.05). 
AFM analysis and MTT assay also confirmed the role of the extract in amyloid inhibition. Our 
studies showed that the presence of CE did not have any effect on protein stabilization and thus 
directly interact with amyloid structure and inhibit formation of these structures. Furthermore, a 
docking experiment showed that a pi-pi interaction may occur between the aromatic component 
of cinnamaldehyde and W62. Interestingly, W62 is one of the principal aromatic residues that 
interact with glycine amide, which is an aggregation suppressor of HEWL. 
Discussion: These observations suggest that aromatic small molecules of CE may directly insert 
into amyloidogenic core of early aggregates and inhibit amyloid fibril formation by disrupting 
the pi-pi interactions.
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1. Introduction
myloid aggregates are the hallmarks of 
many neurodegenerative disorders, includ-
ing Alzheimer’s, Huntington’s and Parkin-
son’s diseases (Chiti & Dobson, 2006). These age-related 
brain disorders are increasing in parallel with the increase 
in life expectancy. It has been estimated that around 81.1 
million people in world will suffer from AD (Alzheimer’s 
disease) by 2040 (Ferri et al., 2006). AD is the most com-A
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mon form of dementia which is associated with neurofi-
brillary tangles and neuritic plaques in postmortem brain 
tissues. These plaques contain extracellular aggregates of 
amyloid beta peptides while tangles are formed by the in-
traneuronal accumulation of insoluble and hyperphosphor-
ylated tau protein (Haass & De Strooper, 1999; Nordberg, 
2004). 
Currently, most treatments used in AD are mostly 
symptomatic therapies, and do not address the underly-
ing causes. Aβ aggregates progressive accumulation is 
believed to be essential in the development of neurode-
generative pathology. Deposition of these aggregates 
triggers a cascade of events including neurotoxicity, 
oxidative damage, and inflammation (Chromy et al., 
2003; J. A. Hardy & Higgins, 1992). Some studies have 
highlighted soluble Aβ oligomers as the primary toxic 
species in AD (Walsh et al., 2002). Based on the above 
information, and in order to prevent or treat AD, differ-
ent strategies have been envisaged to identify inhibitors 
of β-amyloid protein folding and aggregation. As exam-
ples, use of small peptides (as β-sheet blockers) (Gazit, 
2002b; Soto et al., 1998), use of agents that reduce Aβ 
production (γ- and β – secretase inhibitors) (Ghosh, Ku-
maragurubaran, Hong, Koelsh, & Tang, 2008; Walsh et 
al., 2002), ways to increase Aβ clearance (amyloid vac-
cine) (Cao, Lin, Wahi, Jackson, & Potter, 2008; Youm 
et al., 2008), inhibition of Aβ aggregation (non-steroidal 
anti-inflammatory agents) (Blanchard et al., 2004; Walsh 
et al., 2002), use of antioxidants (Cheng, Feng, Zhang, 
& Zhang, 2006; De Felice et al., 2007) and inhibitors 
of tau protein phosphorylation (Dickey & Petrucelli, 
2006) have been studied in this regard. Moreover, there 
are many reports on small organic compounds, including 
Congo red, furan (Estrada & Soto, 2007), indole (Pap-
polla et al., 2002; Ramshini & Ebrahim-Habibi, 2012), 
curcumin (Liu et al., 2012), and multiple synthetic and 
natural compounds (Levine Iii, 2007; Masuda et al., 
2006), which have been tested on the fibril formation of 
different proteins. Before the development of modern 
medicine, people relied on a large spectrum of natural 
remedies for the treatment of chronic illnesses, including 
diseases affecting the central nervous system. 
It has been suggested that some traditional herbs may 
possess anti-aging properties and become potential can-
didates for the treatment of aging –associated diseases 
(Ho, So, & Chang). Moreover, successful treatments for 
dementia have been developed from herbal drugs. Ex-
tracts from Ginkgo biloba (J-Gertz & Kiefer, 2004) and 
Galanthus woronowii (Heinrich & Lee Teoh, 2004), are 
examples of plants that have been used for treatment of 
mild to moderate AD. Michael Adams and his co-work-
ers have reviewed plants that were traditionally used in 
age related brain disorders and have shown the existence 
of common traditional remedies in different societies to 
treat age-related cognitive disorders (Adams, Gmünder, 
& Hamburger, 2007). Cinnamomum verum (Cinnamon) 
is a herb that has been traditionally used by many ancient 
cultures. It has been indicated for a variety of ailments, 
including gastrointestinal problems, urinary infections, 
symptoms of colds and flu, and possesses remarkable 
anti-fungal and anti-bacterial properties (Peterson et al., 
2009). Some studies have shown that Cinnamon was 
also used traditionally in age related brain disorders (Pe-
terson et al., 2009). The polyphenolic molecules that are 
present in the aqueous extract of Cinnamomum, may be 
responsible for the majority of properties of the plant. In 
the present study, the effects of Cinnamomum verum ex-
tract (CE) were characterized on amyloid disaggregation 
of hen egg white lysozyme (HEWL) as a model protein, 
and its possible mechanism of effect was investigated in 
detail.
2. Methods
2.1. Materials
HEWL (EC 3.2.1.17), Congo red and ThT were pur-
chased from Sigma (St Louis, MO, USA). ANS, all salts 
and organic solvents were obtained from Merck (Darm-
stadt, Germany). 
2.2. C. Verum extracts preparation 
The plant material was collected in March 2012 from 
Isfahan Botany herbarium. 30 grams of finely ground C. 
Verum was added to 300 ml of 50 °C nanopure water 
in Soxhlet extractor for 4-5 hours. The extract was fil-
tered and the supernatant was concentrated with a rotary 
evaporator. The extract was then freeze-dried resulting 
in a powder extract and stored in the dark at room tem-
perature. The resulting powder which was weighed and 
re-dissolved in water is referred to as cinnamon extract 
(CE) throughout this study. Aggregation of 2 mg/ml 
HEWL is initiated by the addition of specific quantity of 
the extract (1 mg/ml in final concentration) into reaction 
medium. 
2.3. Amyloid preparation
Protein concentration was determined spectrophoto-
metrically at 280 nm, using an extinction coefficient (ε280) 
of 2.65 L g-1 cm-1 (Sophianopoulos, Rhodes, Holcomb, 
& Van Holde, 1962). lysozyme was dissolved at 2 mg/
mL in 50mM glycine buffer (pH 2.5), and then incubated 
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at 57 °C for the specified durations while stirred gen-
tly by Teflon magnetic bars (Morshedi, Rezaei-Ghaleh, 
Ebrahim-Habibi, Ahmadian, & Nemat-Gorgani, 2007).
2.4. ANS fluorescence spectroscopy
ANS fluorescence experiments were performed on a Cary 
Eclipse VARIAN fluorescence spectrophotometer. ANS 
fluorescence studies were measured using a final ANS 
concentration of 250 μm, and the molar ratio of protein to 
ANS was 1:50. ANS fluorescence emission was scanned 
between 400 and 700 nm with an excitation wavelength 
of 380 nm.
2.5. ThT assay
All fluorescence experiments were carried out on a 
Cary Eclipse VARIAN fluorescence spectrophotometer 
(Mulgrave, Australia) at room temperature. Stock solu-
tion of ThT was prepared in phosphate buffer (10 mM 
sodium phosphate, 150 mM NaCl, pH 7) at a concentra-
tion of 2.5 mM, passed through a 0.45 μm filter paper 
and stored at 4°C. At different time intervals, an aliquot 
(10 μL) of incubated solution was mixed with 490 μl of 
ThT solution in a quartz cuvette with 1 cm path length. 
Fluorescence emission spectra were then taken using 
excitation at 440 nm. The excitation and emission slit 
widths were set as 5 nm and 10 nm, respectively (Nils-
son, 2004).
2.6. CR assay
Samples were prepared as described above. At different 
time intervals, 60 μL aliquots of each sample were mixed 
with 440 μL of a solution containing 20 mM CR, 5 mM 
sodium phosphate buffer, and 150 mM NaCl at pH 7.4. 
The Congo red solution was filtered using a center-glass 
N4 filter. Optical absorption spectra were acquired from 
400 to 700 nm, after a two to three minute equilibration 
at 25°C, using a 10 cm path-length cell and a Cecil 7200 
UV-visible spectrophotometer (England).
2.7. Atomic force Microscopy (AFM).
In order to show HEWL amyloid fibrils morphologies, 
atomic force microscopy was used. For this purpose, an 
aliquot (10μL) from the incubated solution was placed 
on freshly cleaved mica at room temperature. After a 
few minutes mica was slowly washed with 100 μL of 
deionized water, followed by drying with nitrogen gas. 
Each image was acquired in a tapping mode at a scan 
speed of 30 μm/s, loop filter of 3 Hz and force of 200 nN 
with a Dual Scope Probe Scanner (Solver next, model 
NT-MDT, DME, Russia) with an area of 5x5 μm2. Coni-
cal shape silicon tips (mikromasch NSC16) with a reso-
nance frequency of 150 kHz and a nominal constant of 
40 N/m were used.
2.8. 3-(4, 5- dimethylthiazol)-2, 5- diphenyltet-
raazolium bromide (MTT) reduction test
MCF7 cells were cultured in Dulbecco’s Modified Ea-
gle’s Medium (DMEM) F-12 Ham with 25 mM HEPES 
and NaHCO3 (1:1) supplemented with 10% fetal calf se-
Figure 1. Effect of various concentrations of CE on HEWL 
amyloid fibrillation. This result was obtained at pH 2.5 and 
57 °C by monitoring the change in ThT emission enhance-
ment after 48 hours. CE was added at different concentra-
tions at 0.1(2), 0.25(3), 0.5(4) and 1(5) mg/ml. Protein concen-
tration was 2 mg/ml. ThT enhancement of HEWL without 
CE (1) and ThT alone (6) are also shown for comparison.
Figure 2. Study of the quenching activity of CE. HEWL amy-
loid were acquired after 48 hours incubation at pH 2.5 and 
57 °C and immediately monitored by ThT fluorescence as-
say before and after adding CE in final concentration of 1 
mg/ml to the cell. 
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rum (Sigma-Aldrich), 1.0 mM glutamine and antibiotics 
(100 unit/mL penicillin and 100 μg /mL streptomycin). 
The cells were maintained in a 5.0% CO2 humidified 
atmosphere at 37 °C and grown until 80% confluence 
for a maximum of 20 passages. HEWL amyloid samples 
were prepared as described above. The amyloid samples 
were centrifuged and dried under N2 to remove CE, 
dissolved in DMEM at a final lysozyme concentration 
of 2 μ M. Aggregate toxicity was assessed in 96-well 
plates by the MTT assay. Briefly, the cells were seeded 
at 5000 cells per well in 96-well cell culture plates. After 
24 h incubation, growth media was replaced with fresh 
growth medium containing lysozyme (2 μm). After the 
exposure to 2 μm HEWL aggregates for 48 h at 37 °C, 
the medium was removed and MTT solution (5mg/ml in 
PBS) was added to the cells. The cells were incubated at 
37 °C for 4 hours, then the medium was aspirated, and 
the formazan product was solubilized with DMSO. The 
absorption was measured at 570 nm (620nm as a refer-
ence) in an ELISA reader. Cell viability was expressed 
as percent of MTT reduction in treated cells as compared 
to untreated cells (untreated with lysozyme aggregates).
2.9. Docking studies
Autodock vina was used to do the docking experiment 
(Trott & Olson, 2010). The 2VB1.pdb file was used as 
receptor. The protonation state of the protein was adjust-
ed at pH=2.5 with the use of the residue pKa prediction 
module of MOE 2012.10 (Chemical Computing Group 
Inc., Montréal, Canada). Grid box of 40 × 40 × 58 points 
was used with a spacing 1.0 A˚, and enclosed the whole 
molecule. The grid box center location was on x=-1.613, 
y= 14.597, and z=24.37. The ligand (cinnamaldehyde) 
was prepared using MOE 2012.10. Gasteiger charges 
were assigned to protein and ligand molecules. Exhaus-
tiveness was set on 20 and a computer with four proces-
sors was utilized for the computation. 100 poses were 
generated for the ligand; computing ligand interactions 
and preparation of the image representing the best pose 
were performed with MOE 2012.10.
2.10. Statistical analysis
All data are presented as Mean ±SD. The mean values 
were calculated based on the data from at least 3 inde-
pendent experiments. The data were analyzed in SPSS 
16 using descriptive statistics as well as independent 
t-test. The statistical significances were achieved when 
P<0.05. 
3. Results
3.1. Characterization of lysozyme aggregation in 
acidic pH
Both wild-type human lysozyme and HEWL have been 
shown to undergo amyloid aggregation under specific in 
vitro conditions (Arnaudov & de Vries, 2005; Morozo-
va-Roche et al., 2000). Since the structure and folding 
mechanisms of lysozyme have been well studied, the 
enzyme is considered to be a useful model in amyloid-
related research. First, HEWL was driven toward amy-
loid formation by the use of acidic pH (pH=2.5) and high 
temperature (57 °C). Thioflavin T and Congo red were 
used as markers for detection of amyloid fibrillation 
Figure 3. Kinetics of HEWL fibrillation in the presence of 1 
mg/ml CE. Kinetics was followed by monitoring maximal 
ThT emission intensity at various times of incubation at pH 
2.5 and 57 °C (□). HEWL in the absence of CE is indicated by 
(■). The protein concentration was 2 mg/ml.
Figure 4. Effect of CE on HEWL amyloid fibrils when added 
after the nucleation step. CE (with 1mg/ ml final concentra-
tion) was added to HEWL samples incubated for 36 h, at pH 
2.5 and 57 °C. ThT fluorescence changes were then moni-
tored over 48 h incubation in the same condition (□). HEWL 
in the absence of CE is indicated by (■). Protein concentra-
tion was 2 mg/ml.
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(Nilsson, 2004). ThT fluorescence emission recorded for 
48 hours showed a significant increase in ThT fluores-
cence emission (from 28.4±5.2 to 646.6±27.3 a.u.) and 
also the kinetics of amyloid formation was nucleation-
dependent. Furthermore, the Congo red absorbance 
indicated an increase accompanied by gradual higher 
red shift during the incubation time. Both data are in 
accordance with previous reports on HEWL amyloid 
formation (Morshedi et al., 2007). Finally, atomic force 
microscopy (AFM) image of HEWL samples incubated 
in this condition confirmed the formation of long, un-
branched fibrils, which are characteristic of amyloid 
structures.
3.2. Effect of C. verum extract (CE) on fibrillation 
of HEWL
Various concentrations of CE (aqueous extract) rang-
ing from 0.1-1 mg/ml were employed to set the best 
concentration. A dose dependent effect was observed 
(reaching a plateau at 0.5 mg/ml) as shown in Figure 1, 
and concentrations higher than 0.1 mg/ml, significantly 
inhibited the aggregation of HEWL. The one mg/ml con-
centration was used for the subsequent experiments. We 
also designed a control experiment to rule out the pos-
sibility that the low ThT intensity in the fluorescence as-
say might result from a quenching effect of the inhibitor. 
To this end, 1 mg/ml CE was added to HEWL amyloid 
sample and fluorescence was immediately measured. 
No significant quenching effect was observed (Figure 
2). The effect of 1 mg/ml CE on the kinetics of HEWL 
amyloid formation was also investigated through moni-
toring maximal ThT emission intensity over the course 
of 48 hours (Figure 3). As mentioned before, the amy-
loid formation process obeys the characteristic nucle-
ation-dependent pattern, with the three distinct phases 
of initial nucleation, elongation and equilibration clearly 
observed. To assess which phase was inhibited in pres-
ence of CE, the extract was added to HEWL sample af-
ter nucleation phase was completed and fibrillogenesis 
had already started (after 36 hours of incubation). The 
result showed that CE inhibited the polymerization and 
equilibrium phases (Figure 4). In order to determine the 
CE effect on the ultra-structural properties of the HEWL 
assemblies, AFM images in absence (Figure 5A) or pres-
ence (Figure 5B) of the extract were analyzed. While 
mature fibrils were observed in the absence of CE (Fig-
ure 5A), samples containing lysozyme and 1mg/ml CE 
were devoid of fibril and contained only a very small 
amount of small oligomers (Figure 5B).
 3.3. Cell damage induced by lysozyme oligomers 
and protective effect of CE 
To further evaluate whether CE can inhibit oligomers 
toxicity, lysozyme oligomers which were prepared after 
48 h incubation in glycine buffer pH 2.5, 57 °C with and 
without CE (1 mg/ml) were transferred to a physiologi-
cal medium and the resulting suspensions were added to 
the cell culture media of MCF7 cells at a concentration 
of 2 μm (all concentrations refer to monomer concen-
tration). The cell viability was evaluated by MTT assay 
(Mosmann, 1983). Untreated cells did not cause any de-
tectable decrease in the ability of cells to reduce MTT 
(Figure 6). By contrast, the cell viability of MCF7 cells 
Figure 5. AFM images of HEWL aggregates deposited on 
mica following inhibition by CE. AFM samples were taken 
when ThT fluorescence indicated that control samples con-
taining HEWL alone had reached the equilibration phase. 
Control samples showed long and mature fibrils (A). HEWL 
in presence of 1 mg/ml CE after 48 hour incubation at 57 °C 
revealed the presence of small oligomers and disappearance 
of fibrils (B). 
Figure 6. Cytotoxicity of HEWL aggregates. Cell viability 
was determined by the MTT reduction test in MCF7 cells 
exposed to 2 μm native HEWL aggregates incubated for 48 
hours at 57.5 °C, pH 2.5 (bar 2). HEWL aggregates incubated 
for 48 hours at 57.5 °C, pH 2.5 and in presence of 1 mg/ml 
CE (bar 3). The reported values are representative of two 
independent experiments, each carried out four times. Un-
treated cells were assumed to be viable as a control (bar 1).
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were significantly decreased to 38±8.3 % after a 48 h ex-
posure to HEWL aggregates. In presence of CE, the abil-
ity of cells to reduce MTT were increased to 66.5±10%, 
thus the extract could significantly prevent MCF7 
(P<0.05) from the cytotoxicity of lysozyme oligomers 
and improved cell viability.
3.4. CE cannot stabilize native state of HEWL
Small molecules can inhibit amyloid aggregation with 
various mechanisms including stabilization of native 
state, destabilization of nucleus and inhibition of elon-
gation and lateral accumulation of fibrils; some small 
molecules may influence more than one of the steps 
(Li, Zhu, Rajamani, Uversky, & Fink, 2004; Morshedi 
et al., 2007). It is suggested that induction of aggrega-
tion generally requires the presence of partially unfolded 
state (Dobson, 1999). Indeed, low pH induces formation 
of molten globule-like structures in HEWL, in which 
exposure of relatively mobile hydrophobic patches oc-
curs on the protein surface (Cardamone & Puri, 1992). 
Here too, fluorescence measurements involving 8-anili-
nonaphthalene-sulfonate (ANS) a hydrophobic reporter 
probe, revealed exposure of large hydrophobic patches 
on the surface of the protein molecule in the amyloid 
aggregation-prone state (Figure 7). As shown in Figure 
7, the addition of CE into incubation medium did not 
prevent exposure of hydrophobic patches; therefore, it 
seems that the extract couldn’t inhibit HEWL amyloid 
fibril formation by protecting the native protein from 
structural changes.
3.5. Docking studies
Most of cinnamon biological effects are attributed to 
its cinnamaldehyde component. A docking experiment 
was done as a theoretical attempt to further explain the 
positive anti-amyloid effect of cinnamon extract with 
regard to cinnamaldehyde. The best pose of the ligand 
with a scoring of - 7.3 kcal/mol is shown in the HEWL 
structure in Figure 8. This interaction site is relatively 
far from the catalytic residues, but still located in the 
binding site of lysozyme substrates. A putative hydrogen 
bond was detected by the software between A107 back-
bone and the carbonyl group of the ligand, as well as a 
pi-pi interaction between the aromatic component of the 
ligand and W62.
4. Discussion
Since Aβ aggregation and accumulation to amyloid 
plaques is considered to be the initiator of events leading 
to neurotoxicity and the clinical symptoms of Alzheim-
er’s disease, thus the search for anti-amyloid therapies 
has become an important strategy in AD-related re-
search, (Chromy et al., 2003; J. Hardy & Selkoe, 2002; 
J. A. Hardy & Higgins, 1992). Reducing the production 
of the amyloidogenic form of proteins, increasing the 
clearance rate of misfolded or aggregated proteins, or 
stabilizing the native state of amyloidogenic proteins, as 
well as the direct inhibition of the self-assembly process 
(Cohen & Kelly, 2003) have been so far proposed as 
potential therapeutic approaches. Emphasis is currently 
put onto controlling the prefibrillar conformers (soluble 
oligomers) of amyloidogenic proteins, since it has been 
shown that these are usually the most toxic aggregates 
both in vitro and in vivo (Campioni et al.,; Chiti & Dob-
son, 2006; Glabe, 2008). Instead of targeting all possible 
intermolecular contacts, a better way to alter the nucle-
ation pathway and prevent formation of fibrils could be 
the use of small molecules such as sugars, polyols, ami-
no acids, amines, salts, polymers and surfactants which 
disrupt specific intermolecular contacts. Nowadays, 
increasing interest is observed toward herbal medicine, 
since they are often positively perceived as more natu-
ral treatments compared to synthetic drugs. Specifically, 
successful treatments for dementia have been developed 
from herbal drugs (Adams et al., 2007), including CE 
that has been reported to inhibit the tau aggregation pro-
cess (Peterson et al., 2009). 
Analysis of the aqueous extract of Cinnamon has 
showed that it contains proanthocyanidin trimer spe-
cies and cinnamaldehyde and its anti-aggregation activ-
ity was attributed to these compounds (Peterson et al., 
Figure 7. Effect of CE on the surface hydrophobicity of 
HEWL. Changes in ANS emission spectra obtained in the 
presence of HEWL when incubated at pH 2.5 and 57 °C with 
1 mg/ml with (__) and without CE (---). Background ANS 
fluorescence recorded in the absence of the protein is also 
presented. For more details please see materials and meth-
ods.
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2009). Herein we have confirmed that an aqueous ex-
tract of cinnamon can inhibit the aggregation of HEWL 
in vitro. In the present study, we first prepared a HEWL 
amyloid aggregation by using acidic pH and high tem-
perature and formation of amyloid fibrils was verified 
by various techniques, including specific dyes (ThT and 
Congo red). AFM images of HEWL samples confirmed 
the formation of HEWL long, unbranched fibrils. Then 
we showed the anti- aggregation activity of the extract 
on HEWL by ThT fluorimetric assay (Figure 1). After 
examining the inhibitory effect of the extract on the 
HEWL fibrillogenesis at the end point, we studied its ef-
fect on the kinetics of fibrillogenesis. The results showed 
that the compound could significantly inhibit both po-
lymerization and equilibrium phase and the slope of the 
kinetic curve changed too (Figure 2). The suppression 
of ThT intensity was not due to intensity quenching of 
CE (Figure 3). On the other hand, our study showed that 
the extract could also destabilize mature fibrils if added 
to the medium after the nucleation step (Figure 4). We 
performed an AFM assay to qualitatively validate the 
inhibitory potency of CE on HEWL amyloidogenesis. 
Figures 5 A and B clearly demonstrated that CE could 
inhibit formation of mature fibrils. AFM images support-
ed the suggestion that CE blocks lysozyme fibrillation 
in the early stages of elongation, and that formation of 
mature fibrils from oligomers was inhibited. It is widely 
believed that brain amyloidosis begins with the produc-
tion of a soluble native protein that is misfolded to yield 
the precursor for fibril (Chiti, Taddei, Stefani, Dobson, & 
Ramponi, 2001; Dobson, 1999) formations. Our studies 
showed that the presence of CE did not prevent exposure 
of hydrophobic patches in misfolded monomers but in-
stead accentuated it (Figure 6). As demonstrated by Fig-
ures 2, 4 and 6, nucleation, elongation and equilibrium 
phases seem to be affected by the presence of CE. In 
order to evaluate whether CE, which inhibited HEWL 
amyloid production, could prevent the lysozyme-in-
duced cell death, the samples prepared in amyloido-
genic condition (2 mg lysozyme, pH 2.5 after 24 hour) 
in presence or absence of 1 mg /ml CE were assessed 
by performing the MTT reduction test. Prefibrillar sam-
ples without pretreatment with CE were found to cause 
a significant decrease in MTT reduction but aggregates 
pre-incubated with CE were less toxic (Figure 7). Taking 
these finding together, it seems that CE is not capable 
to inhibit HEWL amyloid formation by protecting the 
native protein from structural change (Figure 6) but the 
Figure 8. Interaction site of cinnamaldehyde with HEWL, as detected 
by docking. The ligand is represented with sticks, HEWL secondary 
structure is shown with ribbons and some HEWL residues located in 
the 3.5 A° vicinity of the ligand are visible and labelled. A putative 
hydrogen bond may be formed between A107 and the ligand (shown 
with dots). 
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extract exert its inhibitory effect on other phases of the 
fibrillation process. Several studies have suggested that 
interactions between aromatic units have an important 
role in molecular recognition and self – assembly (Bem-
porad, Taddei, Stefani, & Chiti, 2006; Gazit, 2002a; 
Reches & Gazit, 2006), especially with regard to the 
attractive non-bonded interactions between planar aro-
matic ring (π- π interactions or π-stacking). In the forma-
tion of supramolecular structures, one important factor is 
the steric constrains resulting from π-stacking (Hunter, 
Lawson, Perkins, & Urch, 2001). Based on this potential 
role of π-stacking interactions, which are also present in 
amyloid structures, aromatic small molecules that may 
be capable of blocking π-stacking could be potential can-
didates to control amyloid diseases (Hunter et al., 2001). 
Cinnamaldehyde and proanthocyanidin are aromatic 
small molecules that are contained in CE, with cinna-
maldehyde as the major compound of the effective re-
agents. The theoretical docking experiment that was 
done showed a putative π- π interaction between the 
aromatic component of the ligand and W62, in addition 
to the putative hydrogen bond with A107 backbone. In-
terestingly, W62 is one of the principal aromatic residues 
that interact with glycine amide, which is an aggregation 
suppressor of HEWL (Ito, Shiraki, Makino, Hasegawa, 
& Kumasaka, 2011). In a study which involved indole 
derivatives as anti-amyloid compounds, potential inter-
action of indole-3-carbinol was detected (by a docking 
method) with W63 and W108 (Morshedi et al., 2007), in 
a location close to what we have found here. In conclu-
sion, the results presented demonstrated that CE acts on 
HEWL fibril formation by disrupting initial intermediate 
structures that are formed in the beginning of the process 
and may achieve this effect, at least partly, via disruption 
of vital π- π interaction. 
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